<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Establishing the cause of Cushing syndrome</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Establishing the cause of Cushing syndrome</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Establishing the cause of Cushing syndrome</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Lynnette K Nieman, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">André Lacroix, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Katya Rubinow, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jun 26, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>After the diagnosis of hypercortisolism is established, its cause must be determined  (<a class="graphic graphic_table graphicRef50582" href="/d/graphic/50582.html" rel="external">table 1</a>). All of the biochemical tests for the differential diagnosis of Cushing syndrome take advantage of the physiologic principle that chronic excessive exposure to glucocorticoids (eg, cortisol) suppresses hypothalamic corticotropin-releasing hormone (CRH) and corticotropin (ACTH) secretion. As a result, ACTH and cortisol responses to testing reflect tumoral contributions and not those of normal corticotrophs.</p><p>To ensure that normal corticotroph secretion of ACTH is suppressed, we suggest that urine free cortisol (UFC) or bedtime salivary cortisol be measured weekly for four to six weeks before initiating differential diagnostic testing and to proceed with testing only if consistent hypercortisolism is confirmed (UFC &gt;2-fold normal and bedtime salivary cortisol 1.5-fold normal). When hypercortisolism does not reach this threshold, physiologic, non-neoplastic entities should be excluded. (See  <a class="medical medical_review" href="/d/html/151.html" rel="external">"Establishing the diagnosis of Cushing syndrome"</a>.)</p><p>The approach to establishing the cause of Cushing syndrome will be reviewed here. The causes, pathophysiology, and diagnosis of Cushing syndrome are discussed separately. (See  <a class="medical medical_review" href="/d/html/125.html" rel="external">"Causes and pathophysiology of Cushing syndrome"</a> and  <a class="medical medical_review" href="/d/html/151.html" rel="external">"Establishing the diagnosis of Cushing syndrome"</a>.)</p><p class="headingAnchor" id="H3429362139"><span class="h1">IS HYPERCORTISOLISM ACTH-DEPENDENT OR INDEPENDENT?</span><span class="headingEndMark"> — </span>Cushing syndrome may be caused by excessive corticotropin (ACTH) secretion from a pituitary or nonpituitary ACTH-secreting tumor, which drives adrenal cortisol production (termed ACTH-dependent), or by autonomous adrenal secretion of excessive amounts of cortisol, which is not stimulated by ACTH (termed ACTH-independent)  (<a class="graphic graphic_table graphicRef50582" href="/d/graphic/50582.html" rel="external">table 1</a> and <a class="graphic graphic_figure graphicRef112079" href="/d/graphic/112079.html" rel="external">figure 1</a>) [<a href="#rid1">1,2</a>].</p><p class="headingAnchor" id="H2687711299"><span class="h2">Measure plasma ACTH</span><span class="headingEndMark"> — </span>The first step to distinguish between these is to measure <strong>plasma corticotropin (ACTH)</strong>  (<a class="graphic graphic_algorithm graphicRef79853" href="/d/graphic/79853.html" rel="external">algorithm 1</a>). This test should be performed using a two-site immunoradiometric assay (IRMA) [<a href="#rid3">3</a>] and may be performed in the morning in patients with sustained hypercortisolism. (See  <a class="medical medical_review" href="/d/html/171.html" rel="external">"Measurement of ACTH, CRH, and other hypothalamic and pituitary peptides"</a>.)</p><p>ACTH secretion is episodic in patients with Cushing syndrome of any cause [<a href="#rid4">4</a>]. Because of this, measurement on at least two separate days is recommended.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>ACTH &lt;5 pg/mL (1.1 pmol/L)</strong> – A low plasma ACTH concentration (&lt;5 pg/mL [1.1 pmol/L]) in a hypercortisolemic patient is evidence of ACTH-independent disease. (See <a class="local">'Primary adrenal CS (suppressed ACTH)'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>ACTH &gt;20 pg/mL (4.4 pmol/L)</strong> –<strong> </strong>If the plasma ACTH concentration is above 20 pg/mL (4.4 pmol/L) in a patient with sustained hypercortisolism, one can assume that cortisol secretion is ACTH-dependent (ie, due to pituitary disease or ectopic ACTH or corticotropin-releasing hormone [CRH] secretion). (See <a class="local">'ACTH-dependent CS (ACTH &gt;20 pg/mL)'</a> below.)</p><p></p><p class="bulletIndent1">However, patients with ACTH-independent causes of Cushing syndrome who have cyclic or mild hypercortisolism (and consequently lack suppression of normal corticotrophs) may have normal ACTH values, falsely indicating an ACTH-dependent condition.</p><p></p><p class="headingAnchor" id="H3202036389"><span class="h2">Equivocal results</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>ACTH between 5 and 20 pg/mL (1.1 to 4.4 pmol/L)</strong> – Plasma ACTH values between 5 and 20 pg/mL (1.1 to 4.4 pmol/L) are less definitive but usually indicate that cortisol secretion is ACTH dependent. For these patients we suggest the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If not already done, urinary free cortisol (UFC) or bedtime salivary cortisol should be collected weekly for four to six weeks. ACTH levels should be repeated after four to six weeks of significant hypercortisolism (ie, UFC twice normal and salivary cortisol &gt;50 percent increased above normal).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Measurement of serum dehydroepiandrosterone sulfate (DHEAS) is useful as it is generally decreased (based on an age-specific reference range) in adrenal causes of Cushing syndrome and normal or increased in ACTH-dependent causes [<a href="#rid5">5</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If three ACTH values remain in the intermediate range of 5 to 20 pg/mL, lack of a response to the CRH or <a class="drug drug_general" data-topicid="9330" href="/d/drug information/9330.html" rel="external">desmopressin</a> stimulation test suggests an ACTH-independent etiology. Hypercortisolemic patients with adrenal tumors and most with ectopic ACTH-secreting tumors do not respond. However, some patients with Cushing disease also lack a response. Thus, additional testing should always be performed. CRH is currently unavailable worldwide due to manufacturing issues. Future availability is unknown. (See <a class="local">'CRH stimulation test'</a> below and <a class="local">'Desmopressin stimulation test'</a> below and  <a class="medical medical_review" href="/d/html/158.html" rel="external">"Desmopressin (DDAVP) stimulation test", section on 'ACTH-dependent Cushing syndrome'</a>.)</p><p></p><p class="headingAnchor" id="H1760641735"><span class="h1">ACTH-DEPENDENT CS (ACTH &gt;20 PG/ML)</span><span class="headingEndMark"> — </span>Patients with a plasma corticotropin (ACTH)<strong> </strong>&gt;20 pg/mL (4.4 pmol/L) have ACTH-dependent Cushing syndrome. The great majority of these patients have a pituitary corticotroph adenoma (Cushing disease)  (<a class="graphic graphic_table graphicRef50582" href="/d/graphic/50582.html" rel="external">table 1</a> and <a class="graphic graphic_diagnosticimage graphicRef75003" href="/d/graphic/75003.html" rel="external">image 1</a>) rather than ectopic ACTH secretion. Rarely, ectopic corticotropin-releasing hormone (CRH) secretion may cause Cushing syndrome.</p><p class="headingAnchor" id="H2049174245"><span class="h2">Source of excess ACTH: Pituitary or ectopic?</span><span class="headingEndMark"> — </span>The next step is to determine the source of excess ACTH secretion (pituitary versus ectopic) that is causing the hypercortisolism  (<a class="graphic graphic_algorithm graphicRef79853" href="/d/graphic/79853.html" rel="external">algorithm 1</a>).</p><p class="headingAnchor" id="H2706205614"><span class="h2">Test strategy</span><span class="headingEndMark"> — </span>Various tests, alone or in combination, have been used to distinguish between pituitary and ectopic sources of ACTH. The choice of tests for an individual patient will vary depending on availability, diagnostic accuracy, technical expertise, and risk. Ideally, this decision is made by an endocrinologist with experience in managing Cushing syndrome patients.</p><p>There are three approaches that have been advocated for distinguishing between pituitary and ectopic sources of ACTH:</p><p class="bulletIndent1"><span class="glyph">●</span>Perform noninvasive biochemical testing with CRH (if available) and/or <a class="drug drug_general" data-topicid="9330" href="/d/drug information/9330.html" rel="external">desmopressin</a> (DDAVP) stimulation test(s) and a <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> suppression test. When at least one of these tests suggests Cushing disease, perform pituitary magnetic resonance imaging (MRI) and possible petrosal sinus sampling.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Perform biochemical tests and pituitary MRI, and if Cushing disease is not diagnosed, perform imaging to identify an ectopic source of ACTH. If such a source is not found, proceed to petrosal sinus sampling [<a href="#rid6">6</a>]. This approach should only be undertaken in centers with access to multiple imaging techniques and extensive experience with image interpretation, as small ectopic tumors are easily missed.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Perform pituitary MRI and then petrosal sinus sampling if no mass &gt;6 mm is identified. If petrosal sinus sampling is negative, we perform a <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> suppression test. </p><p></p><p class="headingAnchor" id="H813147477"><span class="h3">Noninvasive biochemical testing</span><span class="headingEndMark"> — </span>No noninvasive test has a high diagnostic accuracy in ACTH-dependent Cushing syndrome, but concordant test results can help distinguish between Cushing disease and ectopic ACTH.</p><p class="headingAnchor" id="H1824309471"><span class="h4">CRH stimulation test</span><span class="headingEndMark"> — </span>Corticotroph tumors, like normal corticotrophs, generally respond to corticotropin-releasing hormone (CRH) stimulation with ACTH secretion, and cortisol increases within 45 minutes after intravenous CRH administration [<a href="#rid7">7-13</a>].</p><p>Hypercortisolemic patients with adrenal tumors and most with ectopic ACTH-secreting tumors do not respond to CRH, because pituitary ACTH secretion is suppressed. However, patients with adrenal tumors would be identified by plasma ACTH measurement and usually would not receive CRH.</p><p>Thus, a response to CRH should differentiate Cushing disease from all other causes of Cushing syndrome  (<a class="graphic graphic_algorithm graphicRef79853" href="/d/graphic/79853.html" rel="external">algorithm 1</a>). However, the criteria for interpretation have varied at different centers, and up to 15 percent of patients with either Cushing disease or ectopic ACTH secretion may be misdiagnosed by the test. Further, CRH is currently not available, and future availability is unknown.</p><p class="headingAnchor" id="H9"><span class="h4">High-dose dexamethasone suppression tests</span><span class="headingEndMark"> — </span>Corticotroph tumors are only relatively resistant to negative feedback regulation by glucocorticoids [<a href="#rid14">14</a>]. In contrast, most nonpituitary tumors associated with the ectopic ACTH syndrome are completely resistant to feedback inhibition [<a href="#rid15">15</a>], with the exception of some carcinoid tumors, usually pulmonary neuroendocrine tumors (NETs) [<a href="#rid16">16,17</a>] (see  <a class="medical medical_review" href="/d/html/125.html" rel="external">"Causes and pathophysiology of Cushing syndrome"</a> and  <a class="medical medical_review" href="/d/html/160.html" rel="external">"Dexamethasone suppression tests", section on 'High-dose DSTs'</a>). As a result, in patients with Cushing disease, serum and urine cortisol values tend to decrease after 8 mg of <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a>. However, up to 50 percent of patients with Cushing disease may fail to respond, and the specificity of this test is less than 100 percent [<a href="#rid18">18</a>], particularly if less stringent criteria (eg, 50 percent suppression) are used to judge the result. (See  <a class="medical medical_review" href="/d/html/160.html" rel="external">"Dexamethasone suppression tests"</a>.)</p><p>Although the "high-dose" <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> test always uses an 8 mg dose, the schedule of administration, endpoints, and route of administration vary. Most endocrinologists use the overnight high-dose dexamethasone suppression test (8 mg dexamethasone given orally at 11 PM to midnight) with serum cortisol obtained the following morning because it is shorter than the standard two-day test and avoids urine collection [<a href="#rid14">14,19</a>]. (See  <a class="medical medical_review" href="/d/html/160.html" rel="external">"Dexamethasone suppression tests"</a>.)</p><p class="headingAnchor" id="H11"><span class="h4">Desmopressin stimulation test</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9330" href="/d/drug information/9330.html" rel="external">Desmopressin</a> (DDAVP), like endogenous vasopressin, also stimulates ACTH release in most patients with Cushing disease and usually induces a response similar to that of CRH [<a href="#rid20">20</a>]. Patients with ectopic ACTH secretion rarely respond, but up to 20 percent of those with Cushing disease do not respond [<a href="#rid21">21</a>]. The test is a reasonable alternative when CRH is not available, depending on the criteria used to judge a response. We do <strong>not</strong> recommend its use if CRH is available, because the diagnostic accuracy of the CRH test has been better characterized. (See  <a class="medical medical_review" href="/d/html/158.html" rel="external">"Desmopressin (DDAVP) stimulation test"</a>.)</p><p class="headingAnchor" id="H3805105990"><span class="h4">Combination testing with CRH or desmopressin and dexamethasone</span><span class="headingEndMark"> — </span>As noted, no noninvasive test has a high diagnostic accuracy in ACTH-dependent Cushing syndrome. Therefore, we recommend using either the CRH test (if available) or the <a class="drug drug_general" data-topicid="9330" href="/d/drug information/9330.html" rel="external">desmopressin</a> test in addition to the <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> suppression test, even in patients who meet criteria for dexamethasone suppression. Another option is to give both desmopressin and CRH together, which may improve sensitivity in Cushing disease [<a href="#rid20">20</a>], but this strategy is limited currently by unavailability of CRH.</p><p>If the two tests (CRH and/or <a class="drug drug_general" data-topicid="9330" href="/d/drug information/9330.html" rel="external">desmopressin</a>, and <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a>) both indicate Cushing disease, rare patients with ectopic ACTH secretion are falsely diagnosed, but a number with Cushing disease are missed. Any other combination of results does not discriminate between the forms of ACTH-dependent Cushing syndrome [<a href="#rid8">8,22</a>].</p><p>As a result, many patients require inferior petrosal sinus sampling (IPSS), and some have advocated for initial use of this procedure in all patients [<a href="#rid23">23</a>]. (See <a class="local">'Petrosal venous sinus catheterization'</a> below.)</p><p class="headingAnchor" id="H272136430"><span class="h4">Not recommended</span><span class="headingEndMark"> — </span>The <a class="drug drug_general" data-topicid="10156" href="/d/drug information/10156.html" rel="external">metyrapone</a> stimulation test was recommended in the past. The test is rarely used now because it does not discriminate well between Cushing disease and ectopic ACTH secretion, the compound is difficult to obtain, access to the necessary assays is limited, and the possible need for inpatient admission is inconvenient [<a href="#rid24">24</a>]. (See  <a class="medical medical_review" href="/d/html/162.html" rel="external">"Metyrapone stimulation tests"</a>.)</p><p class="headingAnchor" id="H4110445674"><span class="h3">Pituitary MRI</span><span class="headingEndMark"> — </span>Unenhanced and gadolinium-enhanced high-resolution MRI of the sella turcica should be obtained for two reasons:</p><p class="bulletIndent1"><span class="glyph">●</span>Before petrosal sinus sampling to exclude a tumor more than 6 mm in size, which might obviate the need for the petrosal sampling. If such a lesion is seen, the diagnosis of Cushing syndrome can be further confirmed with a noninvasive test. This 6 mm cutoff is based upon the observation that approximately 10 percent of healthy individuals have a pituitary lesion on MRI &lt;6 mm [<a href="#rid25">25</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Before transsphenoidal exploration to document the anatomy of the sella turcica.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pituitary imaging is <strong>not</strong> necessary in patients in whom endocrine testing suggests ectopic ACTH secretion if petrosal sinus sampling will not be done.</p><p></p><p>Although MRI is more sensitive than computed tomography (CT) for detecting corticotroph adenomas, it detects only approximately 50 percent of these tumors [<a href="#rid25">25</a>]. In reports from one center, the presence of a lesion on preoperative MRI correlated with adenoma location in 171 of 201 patients (85 percent) with surgically proven Cushing disease [<a href="#rid26">26</a>] but falsely suggested tumor in up to 18 percent of patients with ectopic ACTH secretion [<a href="#rid27">27</a>].</p><p>Dynamic MRI (ie, obtaining images very rapidly after gadolinium administration) or spoiled gradient recalled acquisition MRI techniques may provide slightly greater sensitivity than conventional MRI but yield more false-positive scans [<a href="#rid28">28,29</a>].</p><p>If a microadenoma or no lesion is seen, either IPSS and/or biochemical tests (a high-dose <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> suppression test and a CRH stimulation and/or <a class="drug drug_general" data-topicid="9330" href="/d/drug information/9330.html" rel="external">desmopressin</a> test) should be performed. The choice of testing strategy should take into account the local technical experience with IPSS. If this is lacking, the CRH/desmopressin and dexamethasone test approach is preferred. Alternatively, referral to a center with IPSS experience is an option.</p><p class="headingAnchor" id="H12"><span class="h3">Petrosal venous sinus catheterization</span></p><p class="headingAnchor" id="H3913489459"><span class="h4">Indications</span><span class="headingEndMark"> — </span>Patients with noninvasive testing and imaging consistent with Cushing disease do not need further confirmation with petrosal sinus sampling. (See <a class="local">'Test strategy'</a> above.)</p><p>Some investigators recommend that all patients with ACTH-dependent Cushing syndrome undergo bilateral catheterization of the inferior petrosal venous sinuses [<a href="#rid30">30-34</a>]. However, while petrosal sinus sampling has the best overall diagnostic accuracy (approximately 95 percent when using CRH stimulation), it is more expensive, less safe, and less available than noninvasive tests.</p><p>That said, a significant proportion of patients have one or more negative responses on biochemical testing. These patients are still statistically more likely to have Cushing disease than ectopic ACTH secretion. The choice of additional diagnostic tests will be influenced not only by their availability and cost, but also by other features such as extremely elevated urinary free cortisol (UFC) and plasma ACTH concentrations, hypokalemia, and rapid onset of hypercortisolism, all of which favor the diagnosis of ectopic ACTH secretion.</p><p>Petrosal sinus is indicated to distinguish between a pituitary and ectopic tumoral cause in patients with ACTH-dependent Cushing syndrome in the following situations:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients without a pituitary lesion on MRI, or with a lesion less than 6 mm in diameter.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with a biochemical result(s) consistent with Cushing disease who have undergone subtotal or total hypophysectomy without clinical improvement or any effect on ACTH secretion.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with the above indications and previous petrosal sinus sampling that was technically unsuccessful due to lack of experience, improper sample handling, or lack of prolactin measurements for normalization, or which was done when the patient was not hypercortisolemic [<a href="#rid35">35</a>]. (See <a class="local">'Procedure'</a> below.)</p><p></p><p>Routine petrosal sinus sampling is not indicated in the following situations:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with responses to CRH or <a class="drug drug_general" data-topicid="9330" href="/d/drug information/9330.html" rel="external">desmopressin</a> and <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> that suggest Cushing disease and:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A pituitary tumor &gt;6 mm on MRI – In our opinion, the risk of petrosal venous sampling is rarely justified in a patient with a clear-cut pituitary tumor larger than 6 mm on MRI if the patient (while hypercortisolemic) has responses to CRH or <a class="drug drug_general" data-topicid="9330" href="/d/drug information/9330.html" rel="external">desmopressin</a> and <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> that support the diagnosis of Cushing disease.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A normal pituitary MRI – In patients with a normal pituitary MRI and positive responses to both CRH or <a class="drug drug_general" data-topicid="9330" href="/d/drug information/9330.html" rel="external">desmopressin</a> and <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> are nearly certain to have Cushing disease [<a href="#rid8">8,22</a>]. In this setting, IPSS is not needed to establish the diagnosis. However, there are varying opinions on this approach.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Recurrent Cushing disease if the diagnosis was confirmed by an ACTH-staining corticotroph tumor, or clear remission without a history of cyclic hypercortisolism.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Petrosal venous sinus catheterization should not be performed just to determine the location of the pituitary tumor (there is a 69 percent chance of correctly predicting the location without the aid of any anatomical data).</p><p></p><p class="headingAnchor" id="H167072408"><span class="h4">Procedure</span><span class="headingEndMark"> — </span>The most direct way to demonstrate pituitary ACTH hypersecretion is to document a central-to-peripheral ACTH gradient in the blood draining the tumor. The petrosal venous sinus drains the pituitary via the cavernous sinus [<a href="#rid36">36-38</a>].</p><p>To perform this procedure, catheters are inserted via the jugular or femoral veins into both inferior petrosal veins. It is important that each catheter be in the proper location, not in the jugular bulb or vein, because of the large dilution factor produced by blood returning from other areas of the cranium.</p><p>ACTH is measured in petrosal and peripheral venous plasma before and within 10 to 12 minutes after intravenous administration of CRH (if available), 1 mcg/kg up to 100 mcg. CRH is given to overcome the pulsatility of ACTH secretion and to stimulate its release  (<a class="graphic graphic_figure graphicRef60086" href="/d/graphic/60086.html" rel="external">figure 2</a>).</p><p><a class="drug drug_general" data-topicid="9330" href="/d/drug information/9330.html" rel="external">Desmopressin</a> (10 mcg intravenous) has been used in place of CRH to perform petrosal sinus sampling [<a href="#rid39">39,40</a>]. In a retrospective series of 56 patients with ACTH-dependent Cushing syndrome, desmopressin alone was found to amplify the central-to-peripheral ACTH gradient and to provide sensitivity and specificities similar to reported series using CRH [<a href="#rid41">41</a>]. (See  <a class="medical medical_review" href="/d/html/158.html" rel="external">"Desmopressin (DDAVP) stimulation test"</a>.)</p><p>We continue to recommend the use of CRH during the procedure, if it is available, and if not, <a class="drug drug_general" data-topicid="9330" href="/d/drug information/9330.html" rel="external">desmopressin</a>. The procedure has a lower diagnostic accuracy if only sampling is done and no stimulating factor is used [<a href="#rid38">38</a>].</p><p>Both inferior petrosal sinuses can be catheterized successfully in up to 98 percent of patients, but only when attempted by clinicians who perform the procedure often [<a href="#rid42">42</a>]. Cavernous-inferior petrosal sinus venography should be performed at the end of the procedure to document adequate catheter placement and normal venous anatomy.</p><p class="headingAnchor" id="H13"><span class="h4">Interpretation</span></p><p class="headingAnchor" id="H2056886818"><span class="h5">Pituitary source of ACTH</span><span class="headingEndMark"> — </span>A central-to-peripheral plasma corticotropin (ACTH) gradient of ≥2 before CRH administration, or ≥3 after CRH, is diagnostic of a pituitary source of ACTH in patients with consistent hypercortisolism; the gradient is usually much greater, especially after CRH injection [<a href="#rid43">43</a>]. In 14 studies, 759 of a total of 800 patients with proven Cushing disease were correctly identified (95 percent sensitivity), while 115 of 124 with presumed or proven ectopic ACTH secretion were correctly identified (93 percent specificity) [<a href="#rid27">27,42-53</a>].</p><p>The same criteria are used for interpretation of central-to-peripheral ACTH gradients after <a class="drug drug_general" data-topicid="9330" href="/d/drug information/9330.html" rel="external">desmopressin</a>. However, fewer patients with ectopic ACTH secretion have been studied, so the specificity of desmopressin-stimulated petrosal sinus sampling is not well established.</p><p>Patients with a central-to-peripheral plasma ACTH gradient are then referred for transsphenoidal surgery. Some experts also propose transsphenoidal exploration for patients without a gradient. This strategy is most likely to succeed if other testing suggests a pituitary source of ACTH (eg, no ectopic source identified on body imaging, peripheral ACTH levels during petrosal sampling increase significantly with CRH stimulation, and the <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> suppression test supports a pituitary etiology) [<a href="#rid54">54</a>].</p><p class="headingAnchor" id="H2771568764"><span class="h5">Tumor localization within the sella</span><span class="headingEndMark"> — </span>Some studies have shown that a gradient of ≥1.4 between the ACTH concentrations in the two sinuses predicted the side of the tumor with up to 71 percent accuracy if catheters were appropriately placed [<a href="#rid43">43</a>]. However, others have not found such strong predictive values [<a href="#rid31">31,50,55</a>]. In the largest series, the location of the tumor was correctly predicted by a gradient of ≥1.4 in 69 percent of 396 patients with a lateral tumor. Left-sided and consistent lateralization improved the positive predictive values to 76 and 72 percent, respectively [<a href="#rid26">26</a>].</p><p class="headingAnchor" id="H14"><span class="h5">False negatives</span><span class="headingEndMark"> — </span>False-negative results likely result from poor catheter placement or anomalous or asymmetric venous drainage. A false-negative result was found in 0.8 percent in one series of 501 patients but in 11 percent of another series of 78 patients with Cushing disease [<a href="#rid46">46,54</a>]. Thus, lack of a central-to-peripheral gradient on IPSS is useful only if cavernous-inferior petrosal sinus venography demonstrates normal and symmetrical venous drainage [<a href="#rid30">30-32</a>]. In one study, a peak petrosal sinus ACTH concentration (before or after CRH) of &lt;400 pg/mL (88 pmol/L) was found in all 10 of 501 patients with a false-negative result. Thus, low IPSS ACTH values in the setting of a negative response should prompt reconsideration of results [<a href="#rid26">26</a>].</p><p>Prolactin measurement of inferior petrosal sinus samples may help to validate IPSS results in the absence of a central-to-peripheral gradient. In one study of 33 patients with Cushing disease and 5 with ectopic ACTH secretion, petrosal sinus-to-peripheral ratios for ACTH were normalized to petrosal sinus-to-peripheral ratios for prolactin. Three patients without a central ACTH gradient had ACTH-to-prolactin ratios within the range of patients with Cushing disease and were cured after pituitary surgery [<a href="#rid56">56</a>]. Another three studies endorse the approach [<a href="#rid57">57-59</a>], including one that used <a class="drug drug_general" data-topicid="9330" href="/d/drug information/9330.html" rel="external">desmopressin</a> stimulation instead of CRH [<a href="#rid60">60</a>]. However, while this is a promising approach, the specific criteria for interpretation vary among centers. Because repeat petrosal sinus sampling is costly and increases risk, we recommend drawing the samples for prolactin and sending them for assay only if the ACTH results do not show a gradient. This minimizes the overall cost of the procedure. Additionally, if there is a central-to-peripheral gradient consistent with Cushing disease, there is no need to measure prolactin, even if the anatomy is abnormal or the catheters were incorrectly positioned [<a href="#rid58">58</a>].</p><p class="headingAnchor" id="H15"><span class="h5">False positives</span><span class="headingEndMark"> — </span>False-positive results are rare in patients with ectopic ACTH syndrome or an adrenal tumor. When a false-positive result does occur, it is presumably due to incomplete suppression of pituitary ACTH secretion [<a href="#rid23">23,61</a>]. Because of this concern, we recommend repeat weekly testing of UFC or bedtime salivary cortisol for four to six weeks before IPSS to ensure that the normal corticotrophs are suppressed. (See <a class="local">'Measure plasma ACTH'</a> above.)</p><p class="headingAnchor" id="H17"><span class="h4">Complications</span><span class="headingEndMark"> — </span>When the procedure is performed by an experienced radiologist, the incidence of serious complications, such as a cerebrovascular accident, is 0.2 percent [<a href="#rid62">62</a>]. In one series of 166 patients, transient cranial nerve palsy occurred in one patient [<a href="#rid47">47</a>]. In another series of 44 patients, one developed hemiparesis and gaze palsy after the study [<a href="#rid63">63</a>].</p><p>Pulmonary embolism and deep venous thrombosis have been reported, but their frequency in large series is not known [<a href="#rid64">64,65</a>]. In view of the risk of thromboembolic events, some groups give heparin for anticoagulation before the procedure and protamine afterward to avoid the possibility of inferior petrosal and/or cavernous sinus venous thrombosis, but most do not believe that this is necessary. We recommend its use.</p><p>The frequency of less serious complications, such as inguinal or jugular hematomas, is more common.</p><p class="headingAnchor" id="H18"><span class="h3">Other venous sampling tests</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bilateral internal jugular venous sampling</strong> – Bilateral internal jugular venous sampling has been proposed as a useful alternative test, with the advantages of simplicity, safety, and no requirement for specialized expertise. However, the sensitivity of this test (83 to 87.5 percent) is relatively close to the pretest probability of Cushing disease and is inferior to that of petrosal sinus sampling [<a href="#rid51">51-54,66</a>]. Its utility may be restricted to those patients who would benefit from venous sampling, such as those with conflicting results on noninvasive tests, who do not have access to petrosal sinus sampling.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cavernous sinus sampling</strong> – Cavernous sinus sampling has been evaluated for its ability to localize a tumor. In two large series, the sensitivity and specificity of a cavernous sinus-to-peripheral venous plasma ACTH gradient were similar to those of petrosal sinus sampling. Localization of the adenoma, based on a lateralization ratio of ≥1.4, was correct in 62 to 83 percent in whom tumors were found at surgery [<a href="#rid67">67,68</a>]. However, hemihypophysectomy was curative in only approximately 50 percent of patients when it was based on the location of tumor predicted by cavernous sinus sampling [<a href="#rid68">68</a>]. Thus, this technically more demanding procedure does not appear to have superior diagnostic accuracy or lateralization ability compared with petrosal sinus sampling.</p><p></p><p class="headingAnchor" id="H21"><span class="h1">ECTOPIC ACTH-SECRETING TUMORS</span><span class="headingEndMark"> — </span>The optimal strategy for detecting corticotropin (ACTH)-secreting tumors has not been defined. The available modalities (CT, MRI, positron emission tomography [PET], and <a class="drug drug_general" data-topicid="9714" href="/d/drug information/9714.html" rel="external">octreotide</a> scintigraphy) are complementary. Imaging of the lungs or abdomen is unnecessary in patients who have a positive inferior petrosal sinus sampling (IPSS) test [<a href="#rid69">69</a>]. However, if the diagnostic strategy of noninvasive tests followed by pituitary and whole-body imaging is used, a thin-slice whole-body CT is performed to identify a possible ectopic ACTH-producing tumor [<a href="#rid6">6</a>]. If imaging is performed after petrosal sinus sampling suggests an ectopic tumor, the type and sequence of studies are outlined below.</p><p class="headingAnchor" id="H3746128170"><span class="h2">Anatomic imaging</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chest imaging</strong> – It is cost effective to obtain images of the chest first since most ACTH-secreting tumors are located there. CT and MRI scans can anatomically identify and localize some tumors. In one prospective study, the sensitivity of CT was higher (53 percent) than that of MRI (37 percent), although confidence intervals overlapped [<a href="#rid70">70</a>]. Thus, when resources are constrained, we recommend initial CT imaging of the thorax using thin cuts (1 to 2 mm).</p><p></p><p class="bulletIndent1">Small bronchial carcinoids can be confused with pulmonary vasculature on CT or MRI [<a href="#rid71">71</a>]. Small thymic masses are seen on MRI in approximately one-third of patients with Cushing disease; these are usually not thymic carcinoids but represent residual normal thymic tissue, particularly in patients under the age of 40 years [<a href="#rid72">72</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Abdominal imaging</strong> – Anatomic abdominal imaging (CT, MRI) rarely detects occult ectopic gastrointestinal ACTH-secreting tumors but may reveal pancreatic neuroendocrine tumors, pheochromocytoma or hepatic metastases.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neck and pelvic imaging</strong> – Anatomic imaging (CT, MRI) can detect ectopic ACTH sources such as medullary thyroid cancer and paraganglioma in the neck and neuroendocrine tumors of the gut, ovary, or prostate. Neck and pelvic imaging are often performed only after a potential target is identified by functional images, as these locations are less likely to harbor a tumor than the thorax. (See <a class="local">'Functional imaging'</a> below.)</p><p></p><p class="headingAnchor" id="H4186757050"><span class="h2">Functional imaging</span><span class="headingEndMark"> — </span>These are nuclear medicine techniques that take advantage of functional characteristics of neuroendocrine ACTH-secreting tumors, which take up 18-F-dihydroxy-phenyl-alanine (18F-DOPA), and have somatostatin cell surface receptors. These studies are useful adjunctive means to both validate anatomic findings, or when negative, to evaluate potential false-positive anatomic results.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Somatostatin analogs</strong> – Some ectopic ACTH-secreting tumors can be detected by scintigraphy with 111-In-octreotide or an analog of <a class="drug drug_general" data-topicid="9714" href="/d/drug information/9714.html" rel="external">octreotide</a> ([111-In-diethylene triamine penta-acetic acid-D-Phe-1]-octreotide, or pentetreotide) because, like other neuroendocrine tumors, their cells have cell-surface receptors for somatostatin  (<a class="graphic graphic_diagnosticimage graphicRef70712 graphicRef53633" href="/d/graphic/70712.html" rel="external">image 2A-B</a>) [<a href="#rid73">73-75</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>111-In-pentetreotide scintigraphy</strong> – Pentetreotide is not specific for ACTH-secreting tumors; it is also taken up by non-neuroendocrine tumors, such as breast carcinomas, brain tumors, and malignant lymphomas [<a href="#rid76">76</a>], and by white blood cells in active autoimmune or infectious inflammatory lesions and active and chronic granulomatous lesions [<a href="#rid77">77</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Octreotide</strong><strong> scintigraphy</strong> – The sensitivity of <a class="drug drug_general" data-topicid="9714" href="/d/drug information/9714.html" rel="external">octreotide</a> scintigraphy for detecting occult tumors that secrete ACTH ranges from 30 to 53 percent [<a href="#rid70">70,78-80</a>]. Failure to detect these tumors may be related to their small size or inadequate expression of somatostatin receptors. In three studies, 6 of 30 patients had false-positive results (radiation fibrosis, inflammation, follicular thyroid adenoma, accessory spleen). In a few patients, however, scintigraphy, but not CT or MRI, identified the tumor, and in five patients, negative scintigraphy correctly refuted false-positive CT or MRI scans [<a href="#rid78">78-80</a>].</p><p></p><p class="bulletIndent1">Because of the high false-positive rate, the presence of the tumor ideally should be confirmed by CT or MRI [<a href="#rid81">81,82</a>]. The role of repeat scintigraphy after a negative scan is not known.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>68-Ga DOTATATE PET/CT</strong> – Gallium-68 (Ga-68) DOTA-0-Phe1-Tyr-3 octreotate-PET integrated with CT is an alternative imaging ligand that also binds to somatostatin receptors. It is useful in detecting non-ACTH-secreting medullary thyroid cancer; gastrointestinal, pancreatic, and bronchial neuroendocrine tumors; as well as pheochromocytoma, paraganglioma, meningioma, and oncogenic osteomalacia [<a href="#rid83">83,84</a>]. In one study, <a class="drug drug_general" data-topicid="108440" href="/d/drug information/108440.html" rel="external">Ga-68 DOTATATE</a> identified the suspected tumor in 11 of 17 patients (65 percent) undergoing initial evaluation. Nine of these patients underwent surgery, which confirmed tumor in eight; a false-positive adrenal gland was found in the other patient. Changes in management occurred after scans of 11 patients with a known diagnosis of ectopic ACTH secretion who underwent Ga-68 DOTATATE evaluation during follow-up [<a href="#rid85">85-87</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Not recommended</strong> – In one study (18)F-fluorodeoxyglucose PET did not identify any tumor not shown by CT and/or MRI and, thus, is not recommended for routine use [<a href="#rid70">70</a>].</p><p></p><p class="headingAnchor" id="H107324954"><span class="h1">PRIMARY ADRENAL CS (SUPPRESSED ACTH)</span><span class="headingEndMark"> — </span>A low plasma corticotropin (ACTH) concentration (&lt;5 pg/mL [1.1 pmol/L]) in a hypercortisolemic patient is evidence of ACTH-independent disease; ie, primary adrenal disease, which could include a unilateral adenoma, micro- or macronodular hyperplasia, or adrenocortical carcinoma  (<a class="graphic graphic_table graphicRef50582" href="/d/graphic/50582.html" rel="external">table 1</a>) [<a href="#rid44">44</a>].</p><p class="headingAnchor" id="H3453342287"><span class="h2">Imaging</span><span class="headingEndMark"> — </span>If the patient has ACTH-independent Cushing syndrome (ACTH &lt;5 pg/mL [1.1 pmol/L]), thin-section CT imaging of the adrenal glands is the next step in the evaluation, looking for an adrenal mass  (<a class="graphic graphic_diagnosticimage graphicRef70712 graphicRef53633" href="/d/graphic/70712.html" rel="external">image 2A-B</a>). MRI is <strong>not</strong> recommended as the initial procedure, as it does not provide Hounsfield unit information.</p><p class="bulletIndent1"><span class="glyph">●</span>Adrenal adenomas are typically smaller than carcinomas and have a lower unenhanced CT attenuation value (Hounsfield unit &lt;10) [<a href="#rid88">88</a>]. The presence of necrosis, hemorrhage, and calcification favors a diagnosis of carcinoma [<a href="#rid88">88</a>]. (See  <a class="medical medical_review" href="/d/html/137.html" rel="external">"Clinical presentation and evaluation of adrenocortical tumors"</a> and  <a class="medical medical_review" href="/d/html/153.html" rel="external">"Evaluation and management of the adrenal incidentaloma"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>When the unenhanced CT attenuation values are &gt;10 Hounsfield units, MRI or positron emission tomography (PET) scanning with fluorodeoxyglucose may provide additional information about the benign or malignant nature of a unilateral adrenal tumor [<a href="#rid89">89</a>]. Blood levels of adrenal androgens also may be elevated in patients with adrenal carcinoma. (See  <a class="medical medical_review" href="/d/html/137.html" rel="external">"Clinical presentation and evaluation of adrenocortical tumors", section on 'Radiographic studies'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Bilateral adrenal hyperplasia may be seen on imaging with both primary bilateral macronodular adrenal hyperplasia (PBMAH) and longstanding ACTH-dependent disease  (<a class="graphic graphic_diagnosticimage graphicRef76679 graphicRef75144" href="/d/graphic/76679.html" rel="external">image 3A-B</a>), although patients with PBMAH tend to have nodularity superimposed on the hyperplasia. (See  <a class="medical medical_review" href="/d/html/148.html" rel="external">"Cushing's syndrome due to primary bilateral macronodular adrenal hyperplasia"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Bilateral micronodular adrenal glands containing nodules &lt;1 cm in diameter characterize primary pigmented nodular adrenal hyperplasia (PPNAD), although older patients may also have nodules &gt;1 cm. Adjacent tissue may be either atrophic, in which case the nodules look like beads on a string [<a href="#rid60">60</a>], or the adjacent tissue may be somewhat hyperplastic. (See  <a class="medical medical_review" href="/d/html/152.html" rel="external">"Cushing syndrome due to primary pigmented nodular adrenocortical disease"</a>.)</p><p></p><p class="headingAnchor" id="H3030823891"><span class="h2">Additional evaluation</span><span class="headingEndMark"> — </span>If imaging suggests a unilateral adrenal adenoma, no further testing is needed. Management is reviewed separately. (See  <a class="medical medical_review" href="/d/html/174.html" rel="external">"Overview of the treatment of Cushing syndrome", section on 'Adrenal adenomas'</a>.)</p><p>If bilateral disease or a possible carcinoma is seen, additional testing may be indicated to:</p><p class="bulletIndent1"><span class="glyph">●</span>Stage the possible adrenal cancer. (See  <a class="medical medical_review" href="/d/html/137.html" rel="external">"Clinical presentation and evaluation of adrenocortical tumors", section on 'Staging'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Distinguish whether bilateral masses are both functional, or whether one is a nonfunctioning incidentaloma. (See  <a class="medical medical_review" href="/d/html/153.html" rel="external">"Evaluation and management of the adrenal incidentaloma"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Identify forms of PBMAH that may be amenable to medical treatment. (See  <a class="medical medical_review" href="/d/html/148.html" rel="external">"Cushing's syndrome due to primary bilateral macronodular adrenal hyperplasia"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Determine whether patients with possible PPNAD have components of the Carney complex. (See  <a class="medical medical_review" href="/d/html/152.html" rel="external">"Cushing syndrome due to primary pigmented nodular adrenocortical disease"</a>.)</p><p></p><p class="headingAnchor" id="H1176998413"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/112709.html" rel="external">"Society guideline links: Diagnosis and treatment of Cushing syndrome"</a>.)</p><p class="headingAnchor" id="H443140"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/15600.html" rel="external">"Patient education: Cushing syndrome (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/2173.html" rel="external">"Patient education: Cushing syndrome (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H23"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Does patient have corticotropin (ACTH)-dependent or ACTH-independent disease?</strong>  (<a class="graphic graphic_algorithm graphicRef79853" href="/d/graphic/79853.html" rel="external">algorithm 1</a> and <a class="graphic graphic_table graphicRef50582" href="/d/graphic/50582.html" rel="external">table 1</a>) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Measure plasma ACTH</strong> – The first step is to measure plasma ACTH to determine whether the hypercortisolism is ACTH dependent (ie, due to a pituitary or nonpituitary ACTH-secreting tumor) or ACTH independent (ie, due to an adrenal source) by measuring plasma ACTH. (See <a class="local">'Is hypercortisolism ACTH-dependent or independent?'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>ACTH &lt;5 pg/mL (1.1 pmol/L)</strong> – A low plasma ACTH concentration (&lt;5 pg/mL [1.1 pmol/L]) in a hypercortisolemic patient is evidence of ACTH-independent disease (see <a class="local">'Petrosal venous sinus catheterization'</a> above). CT imaging of the adrenal glands is usually the next diagnostic procedure in these patients. (See <a class="local">'Imaging'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>ACTH &gt;20 pg/mL (4.4 pmol/L)</strong> – If the plasma ACTH concentration is above 20 pg/mL (4.4 pmol/L) in a patient with sustained hypercortisolism, one can assume that cortisol secretion is ACTH-dependent (ie, due to pituitary disease or ectopic ACTH or corticotropin-releasing hormone [CRH] secretion). (See <a class="local">'ACTH-dependent CS (ACTH &gt;20 pg/mL)'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>ACTH between 5 and 20 pg/mL (1.1 to 4.4 pmol/L)</strong> – Patients with an intermediate plasma ACTH concentration, 5 to 20 pg/mL (1.1 to 4.4 pmol/L), should undergo repeat testing of ACTH concentrations after four to six weekly urine free cortisol (UFC) or bedtime salivary cortisol values are elevated. If the value remains in the intermediate range, CRH (if available) or <a class="drug drug_general" data-topicid="9330" href="/d/drug information/9330.html" rel="external">desmopressin</a> stimulation testing is helpful. The presence of an ACTH response suggests Cushing disease, while the absence of a response suggests adrenal disease or ectopic ACTH secretion. (See <a class="local">'Noninvasive biochemical testing'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Serum DHEAS </strong>–<strong> </strong>Measurement of serum dehydroepiandrosterone sulfate (DHEAS) is useful as it is generally decreased (based on an age-specific reference range) in adrenal causes of Cushing syndrome and normal or increased in ACTH-dependent causes.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with ACTH</strong>-<strong>dependent disease</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Source of excess ACTH: Pituitary or ectopic?</strong> – Various tests, alone or in combination, have been used to distinguish between pituitary and ectopic sources of ACTH. The choice of tests for an individual patient will vary depending on availability, diagnostic accuracy, technical expertise, and risk. There are several approaches that have been advocated for distinguishing between pituitary and ectopic sources of ACTH:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Perform noninvasive biochemical testing with CRH (if available) and/or <a class="drug drug_general" data-topicid="9330" href="/d/drug information/9330.html" rel="external">desmopressin</a> (DDAVP) and <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> suppression. When at least one of these tests suggests Cushing disease, perform pituitary MRI and possible petrosal sinus sampling.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Perform biochemical tests and pituitary MRI, and if Cushing disease is not diagnosed, perform imaging to identify an ectopic source of ACTH. If such a source is not found, proceed to petrosal sinus sampling [<a href="#rid6">6</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Pituitary MRI</strong> – Patients with ACTH-dependent disease (ACTH &gt;20 pg/mL [&gt;4.4 pmol/L]) should undergo a pituitary MRI. If a clear pituitary lesion &gt;6 mm is identified and high-dose <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> and CRH or <a class="drug drug_general" data-topicid="9330" href="/d/drug information/9330.html" rel="external">desmopressin</a> tests are consistent with Cushing disease, no further diagnostic tests are required. (See <a class="local">'Pituitary MRI'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Noninvasive testing</strong> – The remaining majority of patients with ACTH-dependent disease (ACTH &gt;20 pg/mL [&gt;4.4 pmol/L]) should undergo noninvasive tests (a high-dose <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> suppression test and CRH or <a class="drug drug_general" data-topicid="9330" href="/d/drug information/9330.html" rel="external">desmopressin</a> stimulation test) and/or inferior petrosal sinus sampling (IPSS). (See <a class="local">'ACTH-dependent CS (ACTH &gt;20 pg/mL)'</a> above.)</p><p></p><p class="bulletIndent2">Suppression of cortisol during <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> administration, as well as increases in ACTH and cortisol after CRH or <a class="drug drug_general" data-topicid="9330" href="/d/drug information/9330.html" rel="external">desmopressin</a> administration, are consistent with the diagnosis of a pituitary adenoma (Cushing disease). (See <a class="local">'Noninvasive biochemical testing'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Petrosal venous sinus sampling</strong> – Petrosal venous sinus sampling with CRH or <a class="drug drug_general" data-topicid="9330" href="/d/drug information/9330.html" rel="external">desmopressin</a> stimulation is recommended for patients with unclear MRI (lesions &lt;6 mm) or nonconcordant noninvasive tests to distinguish between Cushing disease and ectopic ACTH secretion. (See <a class="local">'Petrosal venous sinus catheterization'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Further evaluation for possible ectopic ACTH-secreting tumors</strong> – The optimal strategy for detecting ACTH-secreting tumors has not been defined. The available modalities (CT, MRI, positron emission tomography [PET], and <a class="drug drug_general" data-topicid="9714" href="/d/drug information/9714.html" rel="external">octreotide</a> scintigraphy) are complementary. Imaging of the lungs or abdomen is unnecessary in patients who have a positive IPSS test. However, if the diagnostic strategy of noninvasive tests followed by pituitary and whole-body imaging is used, a thin-slice whole-body CT is performed to identify a possible ectopic ACTH-producing tumor. If imaging is performed after petrosal sinus sampling suggests an ectopic tumor, the type and sequence of studies are outlined above. (See <a class="local">'Ectopic ACTH-secreting tumors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with ACTH-independent disease</strong> – If the patient has ACTH-independent Cushing syndrome (ACTH &lt;5 pg/mL [1.1 pmol/L]), thin-section CT imaging of the adrenal glands is the next step in the evaluation, looking for an adrenal mass  (<a class="graphic graphic_diagnosticimage graphicRef70712 graphicRef53633" href="/d/graphic/70712.html" rel="external">image 2A-B</a>). MRI is <strong>not</strong> recommended as the initial procedure, as it does not provide Hounsfield unit information. (See <a class="local">'Primary adrenal CS (suppressed ACTH)'</a> above.)</p><p></p><p class="headingAnchor" id="H4283422428"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The views expressed in this topic are those of the author(s) and do not reflect the official views or policy of the United States Government or its components.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Lacroix A, Feelders RA, Stratakis CA, Nieman LK. Cushing's syndrome. Lancet 2015; 386:913.</a></li><li><a class="nounderline abstract_t">Sharma ST, AACE Adrenal Scientific Committee. AN INDIVIDUALIZED APPROACH TO THE EVALUATION OF CUSHING SYNDROME. Endocr Pract 2017; 23:726.</a></li><li><a class="nounderline abstract_t">Raff H, Findling JW. A new immunoradiometric assay for corticotropin evaluated in normal subjects and patients with Cushing's syndrome. Clin Chem 1989; 35:596.</a></li><li><a class="nounderline abstract_t">Van Cauter E, Refetoff S. Evidence for two subtypes of Cushing's disease based on the analysis of episodic cortisol secretion. N Engl J Med 1985; 312:1343.</a></li><li><a class="nounderline abstract_t">Hong AR, Kim JH, Hong ES, et al. Limited Diagnostic Utility of Plasma Adrenocorticotropic Hormone for Differentiation between Adrenal Cushing Syndrome and Cushing Disease. Endocrinol Metab (Seoul) 2015; 30:297.</a></li><li><a class="nounderline abstract_t">Frete C, Corcuff JB, Kuhn E, et al. Non-invasive Diagnostic Strategy in ACTH-dependent Cushing's Syndrome. J Clin Endocrinol Metab 2020; 105.</a></li><li><a class="nounderline abstract_t">Reimondo G, Paccotti P, Minetto M, et al. The corticotrophin-releasing hormone test is the most reliable noninvasive method to differentiate pituitary from ectopic ACTH secretion in Cushing's syndrome. Clin Endocrinol (Oxf) 2003; 58:718.</a></li><li><a class="nounderline abstract_t">Nieman LK, Chrousos GP, Oldfield EH, et al. The ovine corticotropin-releasing hormone stimulation test and the dexamethasone suppression test in the differential diagnosis of Cushing's syndrome. Ann Intern Med 1986; 105:862.</a></li><li><a class="nounderline abstract_t">Nieman LK, Oldfield EH, Wesley R, et al. A simplified morning ovine corticotropin-releasing hormone stimulation test for the differential diagnosis of adrenocorticotropin-dependent Cushing's syndrome. J Clin Endocrinol Metab 1993; 77:1308.</a></li><li><a class="nounderline abstract_t">Tsagarakis S, Tsigos C, Vasiliou V, et al. The desmopressin and combined CRH-desmopressin tests in the differential diagnosis of ACTH-dependent Cushing's syndrome: constraints imposed by the expression of V2 vasopressin receptors in tumors with ectopic ACTH secretion. J Clin Endocrinol Metab 2002; 87:1646.</a></li><li><a class="nounderline abstract_t">Orth DN, DeBold CR, DeCherney GS, et al. Pituitary microadenomas causing Cushing's disease respond to corticotropin-releasing factor. J Clin Endocrinol Metab 1982; 55:1017.</a></li><li><a class="nounderline abstract_t">Newell-Price J, Morris DG, Drake WM, et al. Optimal response criteria for the human CRH test in the differential diagnosis of ACTH-dependent Cushing's syndrome. J Clin Endocrinol Metab 2002; 87:1640.</a></li><li><a class="nounderline abstract_t">Pecori Giraldi F, Invitti C, Cavagnini F, Study Group of the Italian Society of Endocrinology on the Pathophysiology of the Hypothalamic-pituitary-adrenal axis. The corticotropin-releasing hormone test in the diagnosis of ACTH-dependent Cushing's syndrome: a reappraisal. Clin Endocrinol (Oxf) 2001; 54:601.</a></li><li><a class="nounderline abstract_t">LIDDLE GW. Tests of pituitary-adrenal suppressibility in the diagnosis of Cushing's syndrome. J Clin Endocrinol Metab 1960; 20:1539.</a></li><li><a class="nounderline abstract_t">Liddle GW, Nicholson WE, Island DP, et al. Clinical and laboratory studies of ectopic humoral syndromes. Recent Prog Horm Res 1969; 25:283.</a></li><li><a class="nounderline abstract_t">Strott CA, Nugent CA, Tyler FH. Cushing's syndrome caused by bronchial adenomas. Am J Med 1968; 44:97.</a></li><li><a class="nounderline abstract_t">Malchoff CD, Orth DN, Abboud C, et al. Ectopic ACTH syndrome caused by a bronchial carcinoid tumor responsive to dexamethasone, metyrapone, and corticotropin-releasing factor. Am J Med 1988; 84:760.</a></li><li><a class="nounderline abstract_t">Aron DC, Raff H, Findling JW. Effectiveness versus efficacy: the limited value in clinical practice of high dose dexamethasone suppression testing in the differential diagnosis of adrenocorticotropin-dependent Cushing's syndrome. J Clin Endocrinol Metab 1997; 82:1780.</a></li><li><a class="nounderline abstract_t">Dichek HL, Nieman LK, Oldfield EH, et al. A comparison of the standard high dose dexamethasone suppression test and the overnight 8-mg dexamethasone suppression test for the differential diagnosis of adrenocorticotropin-dependent Cushing's syndrome. J Clin Endocrinol Metab 1994; 78:418.</a></li><li><a class="nounderline abstract_t">Dickstein G, DeBold CR, Gaitan D, et al. Plasma corticotropin and cortisol responses to ovine corticotropin-releasing hormone (CRH), arginine vasopressin (AVP), CRH plus AVP, and CRH plus metyrapone in patients with Cushing's disease. J Clin Endocrinol Metab 1996; 81:2934.</a></li><li><a class="nounderline abstract_t">Vassiliadi DA, Tsagarakis S. DIAGNOSIS OF ENDOCRINE DISEASE: The role of the desmopressin test in the diagnosis and follow-up of Cushing's syndrome. Eur J Endocrinol 2018; 178:R201.</a></li><li><a class="nounderline abstract_t">Hermus AR, Pieters GF, Pesman GJ, et al. The corticotropin-releasing-hormone test versus the high-dose dexamethasone test in the differential diagnosis of Cushing's syndrome. Lancet 1986; 2:540.</a></li><li><a class="nounderline abstract_t">Findling JW, Raff H. Diagnosis and differential diagnosis of Cushing's syndrome. Endocrinol Metab Clin North Am 2001; 30:729.</a></li><li><a class="nounderline abstract_t">Avgerinos PC, Yanovski JA, Oldfield EH, et al. The metyrapone and dexamethasone suppression tests for the differential diagnosis of the adrenocorticotropin-dependent Cushing syndrome: a comparison. Ann Intern Med 1994; 121:318.</a></li><li><a class="nounderline abstract_t">Hall WA, Luciano MG, Doppman JL, et al. Pituitary magnetic resonance imaging in normal human volunteers: occult adenomas in the general population. Ann Intern Med 1994; 120:817.</a></li><li><a class="nounderline abstract_t">Wind JJ, Lonser RR, Nieman LK, et al. The lateralization accuracy of inferior petrosal sinus sampling in 501 patients with Cushing's disease. J Clin Endocrinol Metab 2013; 98:2285.</a></li><li><a class="nounderline abstract_t">Ilias I, Torpy DJ, Pacak K, et al. Cushing's syndrome due to ectopic corticotropin secretion: twenty years' experience at the National Institutes of Health. J Clin Endocrinol Metab 2005; 90:4955.</a></li><li><a class="nounderline abstract_t">Tabarin A, Laurent F, Catargi B, et al. Comparative evaluation of conventional and dynamic magnetic resonance imaging of the pituitary gland for the diagnosis of Cushing's disease. Clin Endocrinol (Oxf) 1998; 49:293.</a></li><li><a class="nounderline abstract_t">Patronas N, Bulakbasi N, Stratakis CA, et al. Spoiled gradient recalled acquisition in the steady state technique is superior to conventional postcontrast spin echo technique for magnetic resonance imaging detection of adrenocorticotropin-secreting pituitary tumors. J Clin Endocrinol Metab 2003; 88:1565.</a></li><li><a class="nounderline abstract_t">McCance DR, McIlrath E, McNeill A, et al. Bilateral inferior petrosal sinus sampling as a routine procedure in ACTH-dependent Cushing's syndrome. Clin Endocrinol (Oxf) 1989; 30:157.</a></li><li><a class="nounderline abstract_t">Tabarin A, Greselle JF, San-Galli F, et al. Usefulness of the corticotropin-releasing hormone test during bilateral inferior petrosal sinus sampling for the diagnosis of Cushing's disease. J Clin Endocrinol Metab 1991; 73:53.</a></li><li><a class="nounderline abstract_t">Mamelak AN, Dowd CF, Tyrrell JB, et al. Venous angiography is needed to interpret inferior petrosal sinus and cavernous sinus sampling data for lateralizing adrenocorticotropin-secreting adenomas. J Clin Endocrinol Metab 1996; 81:475.</a></li><li><a class="nounderline abstract_t">Findling JW, Aron DC, Tyrrell JB, et al. Selective venous sampling for ACTH in Cushing's syndrome: differentiation between Cushing disease and the ectopic ACTH syndrome. Ann Intern Med 1981; 94:647.</a></li><li><a class="nounderline abstract_t">Findling JW, Kehoe ME, Shaker JL, Raff H. Routine inferior petrosal sinus sampling in the differential diagnosis of adrenocorticotropin (ACTH)-dependent Cushing's syndrome: early recognition of the occult ectopic ACTH syndrome. J Clin Endocrinol Metab 1991; 73:408.</a></li><li><a class="nounderline abstract_t">Albani A, Berr CM, Beuschlein F, et al. A pitfall of bilateral inferior petrosal sinus sampling in cyclic Cushing's syndrome. BMC Endocr Disord 2019; 19:105.</a></li><li><a class="nounderline abstract_t">Doppman JL, Oldfield E, Krudy AG, et al. Petrosal sinus sampling for Cushing syndrome: anatomical and technical considerations. Work in progress. Radiology 1984; 150:99.</a></li><li><a class="nounderline abstract_t">Oldfield EH, Girton ME, Doppman JL. Absence of intercavernous venous mixing: evidence supporting lateralization of pituitary microadenomas by venous sampling. J Clin Endocrinol Metab 1985; 61:644.</a></li><li><a class="nounderline abstract_t">Oldfield EH, Chrousos GP, Schulte HM, et al. Preoperative lateralization of ACTH-secreting pituitary microadenomas by bilateral and simultaneous inferior petrosal venous sinus sampling. N Engl J Med 1985; 312:100.</a></li><li><a class="nounderline abstract_t">Castinetti F, Morange I, Dufour H, et al. Desmopressin test during petrosal sinus sampling: a valuable tool to discriminate pituitary or ectopic ACTH-dependent Cushing's syndrome. Eur J Endocrinol 2007; 157:271.</a></li><li><a class="nounderline abstract_t">Tsagarakis S, Vassiliadi D, Kaskarelis IS, et al. The application of the combined corticotropin-releasing hormone plus desmopressin stimulation during petrosal sinus sampling is both sensitive and specific in differentiating patients with Cushing's disease from patients with the occult ectopic adrenocorticotropin syndrome. J Clin Endocrinol Metab 2007; 92:2080.</a></li><li><a class="nounderline abstract_t">Machado MC, de Sa SV, Domenice S, et al. The role of desmopressin in bilateral and simultaneous inferior petrosal sinus sampling for differential diagnosis of ACTH-dependent Cushing's syndrome. Clin Endocrinol (Oxf) 2007; 66:136.</a></li><li><a class="nounderline abstract_t">Kaltsas GA, Giannulis MG, Newell-Price JD, et al. A critical analysis of the value of simultaneous inferior petrosal sinus sampling in Cushing's disease and the occult ectopic adrenocorticotropin syndrome. J Clin Endocrinol Metab 1999; 84:487.</a></li><li><a class="nounderline abstract_t">Oldfield EH, Doppman JL, Nieman LK, et al. Petrosal sinus sampling with and without corticotropin-releasing hormone for the differential diagnosis of Cushing's syndrome. N Engl J Med 1991; 325:897.</a></li><li><a class="nounderline abstract_t">Invitti C, Pecori Giraldi F, de Martin M, Cavagnini F. Diagnosis and management of Cushing's syndrome: results of an Italian multicentre study. Study Group of the Italian Society of Endocrinology on the Pathophysiology of the Hypothalamic-Pituitary-Adrenal Axis. J Clin Endocrinol Metab 1999; 84:440.</a></li><li><a class="nounderline abstract_t">Wiggam MI, Heaney AP, McIlrath EM, et al. Bilateral inferior petrosal sinus sampling in the differential diagnosis of adrenocorticotropin-dependent Cushing's syndrome: a comparison with other diagnostic tests. J Clin Endocrinol Metab 2000; 85:1525.</a></li><li><a class="nounderline abstract_t">Doppman JL, Chang R, Oldfield EH, et al. The hypoplastic inferior petrosal sinus: a potential source of false-negative results in petrosal sampling for Cushing's disease. J Clin Endocrinol Metab 1999; 84:533.</a></li><li><a class="nounderline abstract_t">Lefournier V, Gatta B, Martinie M, et al. One transient neurological complication (sixth nerve palsy) in 166 consecutive inferior petrosal sinus samplings for the etiological diagnosis of Cushing's syndrome. J Clin Endocrinol Metab 1999; 84:3401.</a></li><li><a class="nounderline abstract_t">Bonelli FS, Huston J 3rd, Carpenter PC, et al. Adrenocorticotropic hormone-dependent Cushing's syndrome: sensitivity and specificity of inferior petrosal sinus sampling. AJNR Am J Neuroradiol 2000; 21:690.</a></li><li><a class="nounderline abstract_t">Booth GL, Redelmeier DA, Grosman H, et al. Improved diagnostic accuracy of inferior petrosal sinus sampling over imaging for localizing pituitary pathology in patients with Cushing's disease. J Clin Endocrinol Metab 1998; 83:2291.</a></li><li><a class="nounderline abstract_t">López J, Barceló B, Lucas T, et al. Petrosal sinus sampling for diagnosis of Cushing's disease: evidence of false negative results. Clin Endocrinol (Oxf) 1996; 45:147.</a></li><li><a class="nounderline abstract_t">Ilias I, Chang R, Pacak K, et al. Jugular venous sampling: an alternative to petrosal sinus sampling for the diagnostic evaluation of adrenocorticotropic hormone-dependent Cushing's syndrome. J Clin Endocrinol Metab 2004; 89:3795.</a></li><li><a class="nounderline abstract_t">Lefournier V, Martinie M, Vasdev A, et al. Accuracy of bilateral inferior petrosal or cavernous sinuses sampling in predicting the lateralization of Cushing's disease pituitary microadenoma: influence of catheter position and anatomy of venous drainage. J Clin Endocrinol Metab 2003; 88:196.</a></li><li><a class="nounderline abstract_t">Colao A, Faggiano A, Pivonello R, et al. Inferior petrosal sinus sampling in the differential diagnosis of Cushing's syndrome: results of an Italian multicenter study. Eur J Endocrinol 2001; 144:499.</a></li><li><a class="nounderline abstract_t">Swearingen B, Katznelson L, Miller K, et al. Diagnostic errors after inferior petrosal sinus sampling. J Clin Endocrinol Metab 2004; 89:3752.</a></li><li><a class="nounderline abstract_t">Batista D, Gennari M, Riar J, et al. An assessment of petrosal sinus sampling for localization of pituitary microadenomas in children with Cushing disease. J Clin Endocrinol Metab 2006; 91:221.</a></li><li><a class="nounderline abstract_t">Findling JW, Kehoe ME, Raff H. Identification of patients with Cushing's disease with negative pituitary adrenocorticotropin gradients during inferior petrosal sinus sampling: prolactin as an index of pituitary venous effluent. J Clin Endocrinol Metab 2004; 89:6005.</a></li><li><a class="nounderline abstract_t">Mulligan GB, Faiman C, Gupta M, et al. Prolactin measurement during inferior petrosal sinus sampling improves the localization of pituitary adenomas in Cushing's disease. Clin Endocrinol (Oxf) 2012; 77:268.</a></li><li><a class="nounderline abstract_t">Sharma ST, Raff H, Nieman LK. Prolactin as a marker of successful catheterization during IPSS in patients with ACTH-dependent Cushing's syndrome. J Clin Endocrinol Metab 2011; 96:3687.</a></li><li><a class="nounderline abstract_t">Grant P, Dworakowska D, Carroll P. Maximizing the accuracy of Inferior petrosal sinus sampling: validation of the use of Prolactin as a marker of pituitary venous effluent in the diagnosis of Cushing's disease. Clin Endocrinol (Oxf) 2012; 76:555.</a></li><li><a class="nounderline abstract_t">Akbari H, Ghorbani M, Kabootari M, et al. Usefulness of prolactin measurement in inferior petrosal sinus sampling with desmopressin for Cushing's syndrome. Br J Neurosurg 2020; 34:253.</a></li><li><a class="nounderline abstract_t">Yamamoto Y, Davis DH, Nippoldt TB, et al. False-positive inferior petrosal sinus sampling in the diagnosis of Cushing's disease. Report of two cases. J Neurosurg 1995; 83:1087.</a></li><li><a class="nounderline abstract_t">Miller DL, Doppman JL, Peterman SB, et al. Neurologic complications of petrosal sinus sampling. Radiology 1992; 185:143.</a></li><li><a class="nounderline abstract_t">Gandhi CD, Meyer SA, Patel AB, et al. Neurologic complications of inferior petrosal sinus sampling. AJNR Am J Neuroradiol 2008; 29:760.</a></li><li><a class="nounderline abstract_t">Obuobie K, Davies JS, Ogunko A, Scanlon MF. Venous thrombo-embolism following inferior petrosal sinus sampling in Cushing's disease. J Endocrinol Invest 2000; 23:542.</a></li><li><a class="nounderline abstract_t">Blevins LS Jr, Clark RV, Owens DS. Thromboembolic complications after inferior petrosal sinus sampling in patients with cushing's syndrome. Endocr Pract 1998; 4:365.</a></li><li><a class="nounderline abstract_t">Erickson D, Huston J 3rd, Young WF Jr, et al. Internal jugular vein sampling in adrenocorticotropic hormone-dependent Cushing's syndrome: a comparison with inferior petrosal sinus sampling. Clin Endocrinol (Oxf) 2004; 60:413.</a></li><li><a class="nounderline abstract_t">Graham KE, Samuels MH, Nesbit GM, et al. Cavernous sinus sampling is highly accurate in distinguishing Cushing's disease from the ectopic adrenocorticotropin syndrome and in predicting intrapituitary tumor location. J Clin Endocrinol Metab 1999; 84:1602.</a></li><li><a class="nounderline abstract_t">Liu C, Lo JC, Dowd CF, et al. Cavernous and inferior petrosal sinus sampling in the evaluation of ACTH-dependent Cushing's syndrome. Clin Endocrinol (Oxf) 2004; 61:478.</a></li><li><a class="nounderline abstract_t">Heaney A, Loughrey G, McCance D, et al. Is whole-lung CT scanning still necessary in all cases of ACTH-dependent Cushing's syndrome in the era of petrosal sinus sampling? QJM 1999; 92:335.</a></li><li><a class="nounderline abstract_t">Pacak K, Ilias I, Chen CC, et al. The role of [(18)F]fluorodeoxyglucose positron emission tomography and [(111)In]-diethylenetriaminepentaacetate-D-Phe-pentetreotide scintigraphy in the localization of ectopic adrenocorticotropin-secreting tumors causing Cushing's syndrome. J Clin Endocrinol Metab 2004; 89:2214.</a></li><li><a class="nounderline abstract_t">Newell-Price J, Trainer P, Besser M, Grossman A. The diagnosis and differential diagnosis of Cushing's syndrome and pseudo-Cushing's states. Endocr Rev 1998; 19:647.</a></li><li><a class="nounderline abstract_t">Hanson JA, Sohaib SA, Newell-Price J, et al. Computed tomography appearance of the thymus and anterior mediastinum in active Cushing's syndrome. J Clin Endocrinol Metab 1999; 84:602.</a></li><li><a class="nounderline abstract_t">de Herder WW, Krenning EP, Malchoff CD, et al. Somatostatin receptor scintigraphy: its value in tumor localization in patients with Cushing's syndrome caused by ectopic corticotropin or corticotropin-releasing hormone secretion. Am J Med 1994; 96:305.</a></li><li><a class="nounderline abstract_t">Phlipponneau M, Nocaudie M, Epelbaum J, et al. Somatostatin analogs for the localization and preoperative treatment of an adrenocorticotropin-secreting bronchial carcinoid tumor. J Clin Endocrinol Metab 1994; 78:20.</a></li><li><a class="nounderline abstract_t">Zemskova MS, Gundabolu B, Sinaii N, et al. Utility of various functional and anatomic imaging modalities for detection of ectopic adrenocorticotropin-secreting tumors. J Clin Endocrinol Metab 2010; 95:1207.</a></li><li><a class="nounderline abstract_t">Kwekkeboom DJ, Krenning EP. Somatostatin receptor imaging. Semin Nucl Med 2002; 32:84.</a></li><li><a class="nounderline abstract_t">Vanhagen PM, Krenning EP, Reubi JC, et al. Somatostatin analogue scintigraphy in granulomatous diseases. Eur J Nucl Med 1994; 21:497.</a></li><li><a class="nounderline abstract_t">Torpy DJ, Chen CC, Mullen N, et al. Lack of utility of (111)In-pentetreotide scintigraphy in localizing ectopic ACTH producing tumors: follow-up of 18 patients. J Clin Endocrinol Metab 1999; 84:1186.</a></li><li><a class="nounderline abstract_t">Tabarin A, Valli N, Chanson P, et al. Usefulness of somatostatin receptor scintigraphy in patients with occult ectopic adrenocorticotropin syndrome. J Clin Endocrinol Metab 1999; 84:1193.</a></li><li><a class="nounderline abstract_t">Reincke M, Allolio B, Arlt W, Körber C. Comment on primary localization of an ectopic ACTH-producing bronchial carcinoid tumor by indium111 pentetreotide scintigraphy. J Clin Endocrinol Metab 1999; 84:3399.</a></li><li><a class="nounderline abstract_t">Howlett TA, Drury PL, Perry L, et al. Diagnosis and management of ACTH-dependent Cushing's syndrome: comparison of the features in ectopic and pituitary ACTH production. Clin Endocrinol (Oxf) 1986; 24:699.</a></li><li><a class="nounderline abstract_t">de Herder WW, Lamberts SW. Tumor localization--the ectopic ACTH syndrome. J Clin Endocrinol Metab 1999; 84:1184.</a></li><li><a class="nounderline abstract_t">Tran K, Khan S, Taghizadehasl M, et al. Gallium-68 Dotatate PET/CT is superior to other imaging modalities in the detection of medullary carcinoma of the thyroid in the presence of high serum calcitonin. Hell J Nucl Med 2015; 18:19.</a></li><li><a class="nounderline abstract_t">Hofman MS, Lau WF, Hicks RJ. Somatostatin receptor imaging with 68Ga DOTATATE PET/CT: clinical utility, normal patterns, pearls, and pitfalls in interpretation. Radiographics 2015; 35:500.</a></li><li><a class="nounderline abstract_t">Wannachalee T, Turcu AF, Bancos I, et al. The Clinical Impact of [68 Ga]-DOTATATE PET/CT for the Diagnosis and Management of Ectopic Adrenocorticotropic Hormone - Secreting Tumours. Clin Endocrinol (Oxf) 2019; 91:288.</a></li><li><a class="nounderline abstract_t">Ceccato F, Cecchin D, Gregianin M, et al. The role of 68Ga-DOTA derivatives PET-CT in patients with ectopic ACTH syndrome. Endocr Connect 2020; 9:337.</a></li><li><a class="nounderline abstract_t">Varlamov E, Hinojosa-Amaya JM, Stack M, Fleseriu M. Diagnostic utility of Gallium-68-somatostatin receptor PET/CT in ectopic ACTH-secreting tumors: a systematic literature review and single-center clinical experience. Pituitary 2019; 22:445.</a></li><li><a class="nounderline abstract_t">Blake MA, Kalra MK, Sweeney AT, et al. Distinguishing benign from malignant adrenal masses: multi-detector row CT protocol with 10-minute delay. Radiology 2006; 238:578.</a></li><li><a class="nounderline abstract_t">Ilias I, Sahdev A, Reznek RH, et al. The optimal imaging of adrenal tumours: a comparison of different methods. Endocr Relat Cancer 2007; 14:587.</a></li></ol></div><div id="topicVersionRevision">Topic 156 Version 19.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26004339" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28614036" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : AN INDIVIDUALIZED APPROACH TO THE EVALUATION OF CUSHING SYNDROME.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2539271" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : A new immunoradiometric assay for corticotropin evaluated in normal subjects and patients with Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3873008" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Evidence for two subtypes of Cushing's disease based on the analysis of episodic cortisol secretion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26248856" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Limited Diagnostic Utility of Plasma Adrenocorticotropic Hormone for Differentiation between Adrenal Cushing Syndrome and Cushing Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32594169" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Non-invasive Diagnostic Strategy in ACTH-dependent Cushing's Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12780748" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : The corticotrophin-releasing hormone test is the most reliable noninvasive method to differentiate pituitary from ectopic ACTH secretion in Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3022629" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : The ovine corticotropin-releasing hormone stimulation test and the dexamethasone suppression test in the differential diagnosis of Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8077325" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : A simplified morning ovine corticotropin-releasing hormone stimulation test for the differential diagnosis of adrenocorticotropin-dependent Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11932296" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : The desmopressin and combined CRH-desmopressin tests in the differential diagnosis of ACTH-dependent Cushing's syndrome: constraints imposed by the expression of V2 vasopressin receptors in tumors with ectopic ACTH secretion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6288750" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Pituitary microadenomas causing Cushing's disease respond to corticotropin-releasing factor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11932295" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Optimal response criteria for the human CRH test in the differential diagnosis of ACTH-dependent Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11380490" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : The corticotropin-releasing hormone test in the diagnosis of ACTH-dependent Cushing's syndrome: a reappraisal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13761950" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Tests of pituitary-adrenal suppressibility in the diagnosis of Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4310919" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Clinical and laboratory studies of ectopic humoral syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4294885" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Cushing's syndrome caused by bronchial adenomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2840823" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Ectopic ACTH syndrome caused by a bronchial carcinoid tumor responsive to dexamethasone, metyrapone, and corticotropin-releasing factor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9177382" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Effectiveness versus efficacy: the limited value in clinical practice of high dose dexamethasone suppression testing in the differential diagnosis of adrenocorticotropin-dependent Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8106630" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : A comparison of the standard high dose dexamethasone suppression test and the overnight 8-mg dexamethasone suppression test for the differential diagnosis of adrenocorticotropin-dependent Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8768855" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Plasma corticotropin and cortisol responses to ovine corticotropin-releasing hormone (CRH), arginine vasopressin (AVP), CRH plus AVP, and CRH plus metyrapone in patients with Cushing's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29472379" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : DIAGNOSIS OF ENDOCRINE DISEASE: The role of the desmopressin test in the diagnosis and follow-up of Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2875282" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : The corticotropin-releasing-hormone test versus the high-dose dexamethasone test in the differential diagnosis of Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11571938" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Diagnosis and differential diagnosis of Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8042820" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : The metyrapone and dexamethasone suppression tests for the differential diagnosis of the adrenocorticotropin-dependent Cushing syndrome: a comparison.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8154641" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Pituitary magnetic resonance imaging in normal human volunteers: occult adenomas in the general population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23553862" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : The lateralization accuracy of inferior petrosal sinus sampling in 501 patients with Cushing's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15914534" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Cushing's syndrome due to ectopic corticotropin secretion: twenty years' experience at the National Institutes of Health.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9861318" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Comparative evaluation of conventional and dynamic magnetic resonance imaging of the pituitary gland for the diagnosis of Cushing's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12679440" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Spoiled gradient recalled acquisition in the steady state technique is superior to conventional postcontrast spin echo technique for magnetic resonance imaging detection of adrenocorticotropin-secreting pituitary tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2558816" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Bilateral inferior petrosal sinus sampling as a routine procedure in ACTH-dependent Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1646218" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Usefulness of the corticotropin-releasing hormone test during bilateral inferior petrosal sinus sampling for the diagnosis of Cushing's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8636253" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Venous angiography is needed to interpret inferior petrosal sinus and cavernous sinus sampling data for lateralizing adrenocorticotropin-secreting adenomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6263140" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Selective venous sampling for ACTH in Cushing's syndrome: differentiation between Cushing disease and the ectopic ACTH syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1649842" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Routine inferior petrosal sinus sampling in the differential diagnosis of adrenocorticotropin (ACTH)-dependent Cushing's syndrome: early recognition of the occult ectopic ACTH syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31640675" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : A pitfall of bilateral inferior petrosal sinus sampling in cyclic Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6316418" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Petrosal sinus sampling for Cushing syndrome: anatomical and technical considerations. Work in progress.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4031009" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Absence of intercavernous venous mixing: evidence supporting lateralization of pituitary microadenomas by venous sampling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2981108" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Preoperative lateralization of ACTH-secreting pituitary microadenomas by bilateral and simultaneous inferior petrosal venous sinus sampling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17766708" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Desmopressin test during petrosal sinus sampling: a valuable tool to discriminate pituitary or ectopic ACTH-dependent Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17356045" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : The application of the combined corticotropin-releasing hormone plus desmopressin stimulation during petrosal sinus sampling is both sensitive and specific in differentiating patients with Cushing's disease from patients with the occult ectopic adrenocorticotropin syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17201813" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : The role of desmopressin in bilateral and simultaneous inferior petrosal sinus sampling for differential diagnosis of ACTH-dependent Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10022405" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : A critical analysis of the value of simultaneous inferior petrosal sinus sampling in Cushing's disease and the occult ectopic adrenocorticotropin syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1652686" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Petrosal sinus sampling with and without corticotropin-releasing hormone for the differential diagnosis of Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10022398" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Diagnosis and management of Cushing's syndrome: results of an Italian multicentre study. Study Group of the Italian Society of Endocrinology on the Pathophysiology of the Hypothalamic-Pituitary-Adrenal Axis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10770192" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Bilateral inferior petrosal sinus sampling in the differential diagnosis of adrenocorticotropin-dependent Cushing's syndrome: a comparison with other diagnostic tests.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10022412" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : The hypoplastic inferior petrosal sinus: a potential source of false-negative results in petrosal sampling for Cushing's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10487721" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : One transient neurological complication (sixth nerve palsy) in 166 consecutive inferior petrosal sinus samplings for the etiological diagnosis of Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10782779" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Adrenocorticotropic hormone-dependent Cushing's syndrome: sensitivity and specificity of inferior petrosal sinus sampling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9661597" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Improved diagnostic accuracy of inferior petrosal sinus sampling over imaging for localizing pituitary pathology in patients with Cushing's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8881446" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Petrosal sinus sampling for diagnosis of Cushing's disease: evidence of false negative results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15292307" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Jugular venous sampling: an alternative to petrosal sinus sampling for the diagnostic evaluation of adrenocorticotropic hormone-dependent Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12519852" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Accuracy of bilateral inferior petrosal or cavernous sinuses sampling in predicting the lateralization of Cushing's disease pituitary microadenoma: influence of catheter position and anatomy of venous drainage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11331216" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Inferior petrosal sinus sampling in the differential diagnosis of Cushing's syndrome: results of an Italian multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15292301" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Diagnostic errors after inferior petrosal sinus sampling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16219718" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : An assessment of petrosal sinus sampling for localization of pituitary microadenomas in children with Cushing disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15579751" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Identification of patients with Cushing's disease with negative pituitary adrenocorticotropin gradients during inferior petrosal sinus sampling: prolactin as an index of pituitary venous effluent.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22243215" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Prolactin measurement during inferior petrosal sinus sampling improves the localization of pituitary adenomas in Cushing's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22031511" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Prolactin as a marker of successful catheterization during IPSS in patients with ACTH-dependent Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22017348" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Maximizing the accuracy of Inferior petrosal sinus sampling: validation of the use of Prolactin as a marker of pituitary venous effluent in the diagnosis of Cushing's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32238018" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Usefulness of prolactin measurement in inferior petrosal sinus sampling with desmopressin for Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7490627" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : False-positive inferior petrosal sinus sampling in the diagnosis of Cushing's disease. Report of two cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1523298" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Neurologic complications of petrosal sinus sampling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18238844" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Neurologic complications of inferior petrosal sinus sampling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11021772" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Venous thrombo-embolism following inferior petrosal sinus sampling in Cushing's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15251709" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Thromboembolic complications after inferior petrosal sinus sampling in patients with cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15049954" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Internal jugular vein sampling in adrenocorticotropic hormone-dependent Cushing's syndrome: a comparison with inferior petrosal sinus sampling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10323387" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Cavernous sinus sampling is highly accurate in distinguishing Cushing's disease from the ectopic adrenocorticotropin syndrome and in predicting intrapituitary tumor location.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15473881" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Cavernous and inferior petrosal sinus sampling in the evaluation of ACTH-dependent Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10616709" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Is whole-lung CT scanning still necessary in all cases of ACTH-dependent Cushing's syndrome in the era of petrosal sinus sampling?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15126544" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : The role of [(18)F]fluorodeoxyglucose positron emission tomography and [(111)In]-diethylenetriaminepentaacetate-D-Phe-pentetreotide scintigraphy in the localization of ectopic adrenocorticotropin-secreting tumors causing Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9793762" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : The diagnosis and differential diagnosis of Cushing's syndrome and pseudo-Cushing's states.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10022423" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Computed tomography appearance of the thymus and anterior mediastinum in active Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8166148" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Somatostatin receptor scintigraphy: its value in tumor localization in patients with Cushing's syndrome caused by ectopic corticotropin or corticotropin-releasing hormone secretion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7904613" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Somatostatin analogs for the localization and preoperative treatment of an adrenocorticotropin-secreting bronchial carcinoid tumor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20089611" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Utility of various functional and anatomic imaging modalities for detection of ectopic adrenocorticotropin-secreting tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11965603" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Somatostatin receptor imaging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8082663" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Somatostatin analogue scintigraphy in granulomatous diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10199751" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Lack of utility of (111)In-pentetreotide scintigraphy in localizing ectopic ACTH producing tumors: follow-up of 18 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10199752" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Usefulness of somatostatin receptor scintigraphy in patients with occult ectopic adrenocorticotropin syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10487718" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Comment on primary localization of an ectopic ACTH-producing bronchial carcinoid tumor by indium111 pentetreotide scintigraphy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3024870" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Diagnosis and management of ACTH-dependent Cushing's syndrome: comparison of the features in ectopic and pituitary ACTH production.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10199750" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Tumor localization--the ectopic ACTH syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25679074" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Gallium-68 Dotatate PET/CT is superior to other imaging modalities in the detection of medullary carcinoma of the thyroid in the presence of high serum calcitonin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25763733" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Somatostatin receptor imaging with 68Ga DOTATATE PET/CT: clinical utility, normal patterns, pearls, and pitfalls in interpretation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31066920" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : The Clinical Impact of [68 Ga]-DOTATATE PET/CT for the Diagnosis and Management of Ectopic Adrenocorticotropic Hormone - Secreting Tumours.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32213660" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : The role of 68Ga-DOTA derivatives PET-CT in patients with ectopic ACTH syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31236798" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Diagnostic utility of Gallium-68-somatostatin receptor PET/CT in ectopic ACTH-secreting tumors: a systematic literature review and single-center clinical experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16371582" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Distinguishing benign from malignant adrenal masses: multi-detector row CT protocol with 10-minute delay.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17914090" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : The optimal imaging of adrenal tumours: a comparison of different methods.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
